Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNUS-2 phase 3 study of ianalumab in active Sjogren's syndrome
MOH_2022-08-09_011965Phase 3Recruiting
- Sponsor
- Novartis
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ianalumab in Sjögren's syndrome (3 arms), sponsored by Novartis. Started Aug 2022; status: recruiting.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on MOH_2022-08-09_011965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-08-09_011965.